GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List (Foley & Lardner LLP)

On February 21, 2025, the FDA declared the semaglutide shortage resolved, stating that supply now meets or exceeds demand. This decision follows ongoing litigation with the Outsourcing Facilities Association (OFA), which filed a new lawsuit challenging the removal. The FDA has extended compounding allowances for state-licensed pharmacies until April 22, 2025, and outsourcing facilities until May 22, 2025. The legal battle over semaglutide’s availability may impact future compounding policies, especially as certain GLP-1 products continue to be compounded in various formulations.